Daniel McIntyre is senior vice president of Public Affairs for Biogen Idec, where he is responsible for global communication, government affairs, employee communication and community relations. He also serves on the board of directors of the Biogen Idec Foundation and is treasurer of the company’s PAC. Dan has more than 30 years of experience in public affairs, at the point where communications, public policy and issues management intersect. His expertise includes pharmaceuticals, biologicals and biotechnology, diagnostics and providers. Dan has held the top global position in communications and/or public policy at Wyeth, Pharmacia, and Bayer Pharmaceutical Division. He has counseled two CEOs during their chairmanships of the pharmaceutical trade association, PhRMA, the Healthcare Institute of New Jersey and the New England Healthcare Institute.
Dan has led patient advocacy programs including “Take It To Heart,” with the National Medical Association and National Black Nurses Association, which screened for health conditions in minority communities; “Operation Clean Hands,” a hygiene education program conducted in partnership with the International Society of Microbiology; and “Parents Empowering Parents” with the National Hemophilia Foundation. He also led the communication team supporting PhRMA in RxResponse, a coalition to ensure pharmaceutical supplies in the event of a natural disaster, pandemic or act of bioterrorism.
Dan’s experience in public and government affairs on high-profile issues covers medical product safety and supply; screening and access to therapies in at-risk communities; conduct and reimbursement of clinical trials in the U.S. and developing countries; and pricing of pharmaceutical and biotechnology therapies. He directed Bayer’s public affairs efforts concerning the contamination of anti-hemophilic factor with HIV/AIDS and a worldwide shortage of immune globulins, which included hearings of U.S. congressional oversight subcommittees and the U.S. Department of Health and Human Services, as well as national media coverage that included 60 Minutes.
Dan also has led public affairs efforts for the first ever worldwide product withdrawal linked to Creutzfeldt-Jakob disease; use of antibiotics in food animals; patent extensions under the FDA Modernization Act of 1997; and anthrax labeling for the antibiotic CIPRO. He was a member of Roche’s first national accounts organization, specializing in health economics and third-party coverage for antibiotics, oncology therapies and patient care under clinical trials.
Dan serves on the executive committee of the Rutgers University Foundation, and is a past member of the boards of Caldwell College, the American Association for World Health, the New England Healthcare Institute (NEHI), and Connecticut United for Research Excellence (CURE). He is an honors graduate of Seton Hall University and holds a master’s in public administration from Rutgers University, where he received the E. Drexel Godfrey Award for Academic Excellence.